Patents by Inventor Elliot F. Hahn

Elliot F. Hahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
    Patent number: 8039019
    Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: October 18, 2011
    Assignee: Andrx Labs, LLC
    Inventor: Elliot F. Hahn
  • Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
    Patent number: 7588779
    Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: September 15, 2009
    Assignee: Andrx Labs, LLC
    Inventor: Elliot F. Hahn
  • Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
    Publication number: 20040166162
    Abstract: The subject invention is multi layer pharmaceutical dosage form comprising at least two layers whereby a proton pump inhibitor is in one distinct layer and an aluminum, magnesium or calcium antacid salt is in a second distinct layer.
    Type: Application
    Filed: January 21, 2004
    Publication date: August 26, 2004
    Inventors: Robert Niecestro, Unchalee Kositprapa, Yoon Oh, Avinash Nangia, John R. Cardinal, Elliot F. Hahn
  • Method and composition for treatment of insulin resistance syndromes
    Patent number: 5422125
    Abstract: A method of treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus, by administering an effective amount of the compound magnesium vanadate. Daily dosage ranges are preferably from about 2 to about 60 mg per kg of patient body weight. Pharmaceutical compositions for use in the method of treatment include magnesium vanadate and at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: June 6, 1995
    Assignee: Baker Norton Pharmaceuticals, Inc.
    Inventors: Jay S. Skyler, Phillip Frost, Elliot F. Hahn